Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum

Vikas Prasad

• Publisher: Springer
• Year: 2024
• Print ISBN:
  9783031335327
• eBook ISBN:
  9783031335334
• Edition: 0
• Topic: Medicine
• Subtopic: Internal Medicine & Diagnosis

This open access book is written by world-renowned experts on radiomolecular precision oncology to celebrate the work, life, principles and ideology of Richard P Baum.
It includes commentaries, reviews and some thought provoking novel ideas on radionuclide precision oncology, covering topics such as various aspects of theranostics and molecular radiotherapy like radiolabeled peptides, radiolabeled antibodies, dosimetry, and quality control as well as the diagnosis and treatment of specific tumor types. Featuring contributions by biologists, physicists, chemists, mathematicians, geneticists, and physicians from a range of specialties, this Festschrift is highly interdisciplinary and will be a valuable resource for future precision oncologists.  

Table of contents

• Cover
• Front Matter
• 1. Rise of the Theranostics Empire: A Commentary on Dr. Baum’s Achievements
• 2. Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment
• 3. Surgery in Combination with Peptide Receptor Radionuclide Therapy: A Novel Approach for the Treatment of Advanced Neuroendocrine Tumours
• 4. From Concept to Clinic and Commercialization: Cowboys Wanted
• 5. From Radiochemistry of the Lanthanides to 225Ac and the Interference with Richard Baum
• 6. “How Do You Feel About Dosimetry?” The Gretchenfrage of Radionuclide Therapy
• 7. The LuGenIum Triptych: Ode to a Theranostic Transcriptome
• 8. A Tree Can Be Recognized by Its Fruit
• 9. IAEA Strategy for Enhancing the Sustainability of Nuclear Medicine in Low- and Middle-Income Countries
• 10. Radionuclide Therapy in Brain Tumours
• 11. Modern Diagnostic and Therapeutic Approaches in Thyroid Diseases: Theranostics and the Changing Role of Radioactive Isotopes
• 12. Cardiotoxicity of Targeted Therapies: Imaging of Heart Does Matter
• 13. The Evolution of n.c.a. 177Lu to n.c.a. 177Lu-Edotreotide for the Treatment of Neuroendocrine Tumours. Sixteen Years of Collaboration Between Zentralklinik Bad Berka and ITM
• 14. Fighting for PET in German Oncological Guidelines and for Its Reimbursement by Statutory Health Insurances
• 15. Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC
• 16. From Radioimmunodetection to Radiomolecular Precision Oncology Via Radionanotargeting by Intelligent Multidisciplinary Radiotheragnostic Nanoparticles
• 17. Nuclear Medicine and Surgery on the Way to Personalized Medicine. Ten Years of Clinical and Translational Oncology and Research
• 18. PSMA Radioligand Therapy: A Revolution in the Precision Radiomolecular Oncology of Prostate Cancer
• 19. The Role of Individuals for Innovation: The Nuclear Medicine Biotope
• 20. Working at Isotopentherapiestation D3: A Daily Challenge or Adventure Never Stops
• 21. Theranostics in Australia: The Importance of Vision and Training, and the Power of Collaboration
• 22. Theranostic Radiopeptides in Nuclear Oncology: Design, Preclinical Screening, and Clinical Translation
• 23. Terbium “Sisters”: More Than just a “Swiss Army Knife”
• 24. High-Performance Radiopharmacy: The Base for Precision Oncology
• 25. Analyzing the Science Footprint of Richard P. Baum
• 26. Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA?
• 27. Sola Dosis Facit Venenum: Dosimetry for Molecular Radiotherapy in Bad Berka
• 28. On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer
• 29. Radioiodine-Labeled Meta-Iodobenzylguanidine for Imaging and Treatment of Pheochromocytoma/Paraganglioma and Neuroblastoma
• 30. A (188)Rejuvenating Journey with Hercules
• 31. CXCR4 Theranostics: A Potential Game Changer in Solid Tumors and Hematological Malignancies
• 32. Can VPAC-Targeted Cu-67-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest
• 33. Evaluation of Real-World Efficiency of 177Lu-PSMA Radioligand Therapy of Metastatic Prostate Cancer
• 34. Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in Primary Neuroendocrine Tumors, Metastases, and Normal Liver Tissue: Is There a Significant Difference?
• 35. Theranostics with Somatostatin Receptor Antagonists
• 36. Molecular In Vitro and In Vivo Diagnostics as the Impartible Basis of Multimodal Therapy Approaches in Precision Oncology
• 37. Molecular Imaging Platform and Radiopharmaceutical Translational Research on Peking University Cancer Hospital
• 38. Is It Possible to Target HER2 Using Affibody Receptor Radionuclide Therapy?